Advanced Glycation End Products Induce Tubular Epithelial-Myofibroblast Transition through the RAGE-ERK1/2 MAP Kinase Signaling Pathway

American Journal of Pathology

Volumn 164, Issue 4, 2004, Pages 1389-1397

  Li, Jin H ^a   Wang, Wansheng ^a   Huang, Xiao R ^a   Oldfield, Matthew ^b   Schmidt, Ann M ^c   Cooper, Mark E ^b   Lan, Hui Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADVANCED GLYCATION END PRODUCT; ALPHA ACTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; KIDNEY TUBULE EPITHELIUM; MESENCHYME; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION;

EID: 1642336325     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63225-7     Document Type: Article

References (43)

1. Bucala R, Cerami A: Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992, 23:1-34
2. Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994, 70:138-151
3. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836-842
4. Cooper ME: Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001, 44:1957-1972
5. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999, 56:1627-1637
6. Essawy M, Soylemzoglu O, Muchaneta-Kubara EC, Shortland J, Brown CB, El Nahas AM: Myofibroblasts and the progression of diabetic nephropathy. Nephrol Dial Transplant 1997, 12:43-50
7. Fogo AB: Diabetic nephropathy: it's in the numbers. Kidney Int 2002, 61:2274-2275
8. Fogo AB: Pathology of progressive nephropathies. Curr Opin Nephrol Hypertens 2000, 9:241-246
9. Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996, 7:2495-2508
10. Badid C, Mounier N, Costa AM, Desmouliere A: Role of myofibroblasts during normal tissue repair and excessive scarring: interest of their assessment in nephropathies. Histol Histopathol 2000, 15:269-280
11. Hewitson TD, Becker GJ: Interstitial myofibroblasts in IgA glomerulonephritis. Am J Nephrol 1995, 15:111-117
12. Yang N, Wu LL, Nikolic-Paterson DJ, Ng YY, Yang WC, Mu W, Gilbert RE, Cooper ME, Atkins RC, Lan HY: Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant 1998, 13:1967-1974
13. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG: Identification and characterization of a fibroblast marker: fSP1. J Cell Biol 1995, 130:393-405
14. Okada H, Danoff TM, Kalluri R, Neilson EG: Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997, 273: F563-F574
15. Ng YY, Huang TP, Yang WC, Chen ZP, Yang AH, Nikolic-Paterson DJ, Atkins RC, Lan HY: Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998, 53:864-876
16. Yang J, Liu Y: Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001, 159:1465-1475
17. Jinde K, Nikolic-Paterson DJ, Huang XR, Sakai H, Kurokawa K, Atkins RC, Lan HY: Tubular phenotypic change in progressive tubulointerstitial fibrosis in human glomerulonephritis. Am J Kidney Dis 2001, 38:761-769
18. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341-350
19. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y: Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 2002, 110:1525-1538
20. Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY: Transforming growth factor-β regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999, 56:1455-1467
21. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG: Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002, 61:1714-1728
22. Fan JM, Huang XR, Ng YY, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY: Interleukin-1 induces tubular epithelial-myofibroblast transdifferentiation through a transforming growth factor-β1-dependent mechanism in vitro. Am J Kidney Dis 2001, 37:820-831
23. Yang J, Liu Y: Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002, 13:96-107
24. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001, 108:1853-1863
25. Morcos M, Sayed AA, Bierhaus A, Yard B, Waldherr R, Merz W, Kloeting I, Schleicher E, Mentz S, Abd el Baki RF, Tritschler H, Kasper M, Schwenger V, Hamann A, Dugi KA, Schmidt AM, Stern D, Ziegler R, Haering HU, Andrassy M, van der Woude F, Nawroth PP: Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002, 51:3532-3544
26. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L: Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-κB transcriptional activation and cytokine secretion. Diabetes 2001, 50:1495-1504
27. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360
28. ras-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997, 272:17810-17814
29. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22:153-183
30. Peyssonnaux C, Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001, 93:53-62
31. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM: Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001, 61:4222-4228
32. Huttunen HJ, Kuja-Panula J, Rauvala H: Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem 2002, 277:38635-38644
33. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY: Smad7 inhibits fibrotic effect of TGF-β on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002, 13:1464-1472
34. Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC: A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 1995, 43:97-102
35. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001, 108: 261-268
36. Park L, Raman KG, Lee KJ, Lu Y, Ferran Jr LJ, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4:1025-1031
37. Schmidt AM, Stern D: M: rAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 2000, 11:368-375
38. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM: Modulation of transforming growth factor β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000, 31:1094-1106
39. Pugliese G, Pricci F, Romeo G, Pugliese F, Mene P, Giannini S, Cresci B, Galli G, Rotella CM, Vlassara H, Di Mario U: Up-regulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997, 46:1881-1887
40. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M: PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995, 48:111-117
41. Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY: Advanced glycation end products activate Smad signaling via TGF-β-dependent and -independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 2004, 18:176-178 [Epub ahead of print April 22, 2003]
42. Bottinger EP, Bitzer M: TGF-β signaling in renal disease. J Am Soc Nephrol 2002, 13:2600-2610
43. Lan HY: Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003, 12:25-29